Valsartan ameliorates the constitutive adipokine expression pattern in mature adipocytes: A role for inverse agonism of the angiotensin II type 1 receptor in obesity

Hypertension Research

Volumn 37, Issue 7, 2014, Pages 621-628

  Hasan, Arif U ^a   Ohmori, Koji ^a   Hashimoto, Takeshi ^a   Kamitori, Kazuyo ^a   Yamaguchi, Fuminori ^a   Ishihara, Yasuhiro ^a   Ishihara, Naoko ^a   Noma, Takahisa ^a   Tokuda, Masaaki ^a   Kohno, Masakazu ^a  

^a KAGAWA UNIVERSITY   (Japan)

Author keywords

adiponectin; constitutive activity; diabetes mellitus; interleukin 6; peroxisome proliferator activated receptor

Indexed keywords

1 (4 DIMETHYLAMINO 3 METHYLBENZYL) 5 DIPHENYLACETYL 4,5,6,7 TETRAHYDRO 1H IMIDAZO[4,5 C]PYRIDINE 6 CARBOXYLIC ACID; ADIPOCYTOKINE; ADIPONECTIN; ANGIOTENSIN 1 RECEPTOR; I KAPPA B ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 6; MITOGEN ACTIVATED PROTEIN KINASE; NUCLEAR FACTOR KAPPA B 1; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; UNCLASSIFIED DRUG; VALSARTAN; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ANGIOTENSIN II; TETRAZOLE DERIVATIVE; VALINE;

ADIPOCYTE; ANIMAL CELL; ARTICLE; CELL MATURATION; CONTROLLED STUDY; COS 7 CELL LINE; CYTOKINE PRODUCTION; ENZYME PHOSPHORYLATION; GENETIC TRANSFECTION; INVERSE AGONISM; MOUSE; MTT ASSAY; NONHUMAN; OBESITY; PROADIPOCYTE; PROTEIN EXPRESSION; PROTEIN SECRETION; SIGNAL TRANSDUCTION; UPREGULATION; 3T3 CELL LINE; ACTIVE TRANSPORT; ANALOGS AND DERIVATIVES; ANIMAL; CHLOROCEBUS AETHIOPS; COS 1 CELL LINE; DRUG EFFECTS; GENETICS; METABOLISM; PHYSIOLOGY;

3T3-L1 CELLS; ACTIVE TRANSPORT, CELL NUCLEUS; ADIPOCYTES; ADIPOKINES; ANGIOTENSIN II; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANIMALS; CERCOPITHECUS AETHIOPS; COS CELLS; DRUG INVERSE AGONISM; INTERLEUKIN-6; MICE; NF-KAPPA B; OBESITY; PPAR GAMMA; RECEPTOR, ANGIOTENSIN, TYPE 1; TETRAZOLES; VALINE;

EID: 84904871097     PISSN: 09169636     EISSN: 13484214     Source Type: Journal    
DOI: 10.1038/hr.2014.51     Document Type: Article

References (35)

1. Jing F, Mogi M, Horiuchi M. Role of renin-angiotensin-aldosterone system in adipose tissue dysfunction. Mol Cell Endocrinol 2012; 378: 23-28.
2. Skurk T, van Harmelen V, Hauner H. Angiotensin II stimulates the release of interleukin-6 and interleukin-8 from cultured human adipocytes by activation of NF-kB. Arterioscler Thromb Vasc Biol 2004; 24: 1199-1203.
3. Hotamisligil GS. Endoplasmic reticulum stress and the inflammatory basis of metabolic disease. Cell 2010; 140: 900-917.
4. Weisberg SP, McCann D, Desai M, Rosenbaum M, Leibel RL, Ferrante AW. Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest 2003; 112: 1796-1808.
5. Zeve D, Tang W, Graff J. Fighting fat with fat: The expanding field of adipose stem cells. Cell Stem Cell 2009; 5: 472-481.
6. Chatterjee TK, Stoll LL, Denning GM, Harrelson A, Blomkalns AL, Idelman G, Rothenberg FG, Neltner B, Romig-Martin SA, Dickson EW, Rudich S, Weintraub NL. Proinflammatory phenotype of perivascular adipocytes: Influence of high-fat feeding. Circ Res 2009; 104: 541-549.
7. Zoico E, Di Francesco V, Olioso D, Fratta Pasini AM, Sepe A, Bosello O, Cinti S, Cominacini L, Zamboni M. In vitro aging of 3T3-L1 mouse adipocytes leads to altered metabolism and response to inflammation. Biogerontology 2010; 11: 111-122.
8. Yasuda N, Akazawa H, Ito K, Shimizu I, Kudo-Sakamoto Y, Yabumoto C, Yano M, Yamamoto R, Ozasa Y, Minamino T, Naito AT, Oka T, Shiojima I, Tamura K, Umemura S, Paradis P, Nemer M, Komuro I. Agonist-independent constitutive activity of angiotensin II receptor promotes cardiac remodeling in mice. Hypertension 2012; 59: 627-633.
9. Akazawa H, Yasuda N, Komuro I. Mechanisms and functions of agonist-independent activation in the angiotensin II type 1 receptor. Mol Cell Endocrinol 2009; 302: 140-147.
10. Brasier AR. The nuclear factor-kB-interleukin-6 signalling pathway mediating vascular inflammation. Cardiovasc Res 2010; 86: 211-218.
11. Evans RM, Barish GD, Wang YX. PPARs and the complex journey to obesity. Nat Med 2004; 10: 355-361.
12. Tang T, Zhang J, Yin J, Staszkiewicz J, Gawronska-Kozak B, Jung DY, Ko HJ, Ong H, Kim JK, Mynatt R, Martin RJ, Keenan M, Gao Z, Ye J. Uncoupling of inflammation and insulin resistance by NF-kB in transgenic mice through elevated energy expenditure. J Biol Chem 2010; 285: 4637-4644.
13. Suzawa M, Takada I, Yanagisawa J, Ohtake F, Ogawa S, Yamauchi T, Kadowaki T, Takeuchi Y, Shibuya H, Gotoh Y, Matsumoto K, Kato S. Cytokines suppress adipogenesis and PPAR-g function through the TAK1/TAB1/NIK cascade. Nat Cell Biol 2003; 5: 224-230.
14. Palomer X, Alvarez-Guardia D, Rodríguez-Calvo R, Coll T, Laguna JC, Davidson MM, Chan TO, Feldman AM, Vázquez-Carrera M. TNF-A reduces PGC-1a expression through NF-kB and p38 MAPK leading to increased glucose oxidation in a human cardiac cell model. Cardiovasc Res 2009; 81: 703-712.
15. Soyal S, Krempler F, Oberkofler H, Patsch W. PGC-1a: A potent transcriptional cofactor involved in the pathogenesis of type 2 diabetes. Diabetologia 2006; 49: 1477-1488.
16. Black HR, Bailey J, Zappe D, Samuel R. Valsartan: more than a decade of experience. Drugs 2009; 69: 2393-2414.
17. Cole BK, Keller SR, Wu R, Carter JD, Nadler JL, Nunemaker CS. Valsartan protects pancreatic islets and adipose tissue from the inflammatory and metabolic consequences of a high-fat diet in mice. Hypertension 2010; 55: 715-721.
18. Iwashita M, Sakoda H, Kushiyama A, Fujishiro M, Ohno H, Nakatsu Y, Fukushima T, Kumamoto S, Tsuchiya Y, Kikuchi T, Kurihara H, Akazawa H, Komuro I, Kamata H, Nishimura F, Asano T. Valsartan, independently of AT1 receptor or PPARg, suppresses LPS-induced macrophage activation and improves insulin resistance in cocultured adipocytes. Am J Physiol Endocrinol Metab 2012; 302: E286-E296.
19. Erbe DV, Gartrell K, Zhang YL, Suri V, Kirincich SJ, Will S, Perreault M, Wang S, Tobin JF. Molecular activation of PPARg by angiotensin II type 1-receptor antagonists. Vascul Pharmacol 2006; 45: 154-162.
20. Julius S, Kjeldsen SE, Weber M, Brunner HR, Ekman S, Hansson L, Hua T, Laragh J, McInnes GT, Mitchell L, Plat F, Schork A, Smith B, Zanchetti A Group Vt. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: The value randomised trial. Lancet 2004; 363: 2022-2031.
21. Miura S, Kiya Y, Kanazawa T, Imaizumi S, Fujino M, Matsuo Y, Karnik SS, Saku K. Differential bonding interactions of inverse agonists of angiotensin II type 1 receptor in stabilizing the inactive state. Mol Endocrinol 2008; 22: 139-146.
22. Hasan AU, Ohmori K, Hashimoto T, Kamitori K, Hirata Y, Ishihara Y, Okamoto N, Noma T, Kosaka H, Tokuda M, Kohno M. Pioglitazone promotes preadipocyte proliferation by downregulating p16(Ink4a). Biochem Biophys Res Commun 2011; 411: 375-380.
23. Buler M, Aatsinki SM, Skoumal R, Komka Z, Tóth M, Kerkelä R, Georgiadi A, Kersten S, Hakkola J. Energy-sensing factors coactivator peroxisome proliferatoractivated receptor g coactivator 1-A (PGC-1a) and AMP-activated protein kinase control expression of inflammatory mediators in liver: induction of interleukin 1 receptor antagonist. J Biol Chem 2012; 287: 1847-1860.
24. Kosteli A, Sugaru E, Haemmerle G, Martin JF, Lei J, Zechner R, Ferrante AW. Weight loss and lipolysis promote a dynamic immune response in murine adipose tissue. J Clin Invest 2010; 120: 3466-3479.
25. Heinemeyer T, Wingender E, Reuter I, Hermjakob H, Kel AE, Kel OV, Ignatieva EV, Ananko EA, Podkolodnaya OA, Kolpakov FA, Podkolodny NL, Kolchanov NA. Databases on transcriptional regulation: TRANSFAC, TRRD and COMPEL. Nucleic Acids Res 1998; 26: 362-367.
26. Tilley DG. G protein-dependent and G protein-independent signaling pathways and their impact on cardiac function. Circ Res 2011; 109: 217-230.
27. Tilg H, Moschen AR. Role of adiponectin and PBEF/visfatin as regulators of inflammation: involvement in obesity-associated diseases. Clin Sci (Lond) 2008; 114: 275-288.
28. Matsushita K, Wu Y, Okamoto Y, Pratt RE, Dzau VJ. Local renin angiotensin expression regulates human mesenchymal stem cell differentiation to adipocytes. Hypertension 2006; 48: 1095-1102.
29. Saiki A, Koide N, Watanabe F, Murano T, Miyashita Y, Shirai K. Suppression of lipoprotein lipase expression in 3T3-L1 cells by inhibition of adipogenic differentiation through activation of the renin-angiotensin system. Metabolism 2008; 57: 1093-1100.
30. Hollenberg NK, Parving HH, Viberti G, Remuzzi G, Ritter S, Zelenkofske S, Kandra A, Daley WL, Rocha R. Albuminuria response to very high-dose valsartan in type 2 diabetes mellitus. J Hypertens 2007; 25: 1921-1926.
31. Saydam M, Takka S. Bioavailability file: valsartan. FABAD J Pharm Sci 2007; 32: 185-196.
32. Weiland F, Verspohl EJ. Variety of angiotensin receptors in 3T3-L1 preadipose cells and differentiated adipocytes. Horm Metab Res 2008; 40: 760-766.
33. Siragy HM, El-Kersh MA, De Gasparo M, Webb RL, Carey RM. Differences in AT2- receptor stimulation between AT1-receptor blockers valsartan and losartan quantified by renal interstitial fluid cgmp. J Hypertens 2002; 20: 1157-1163.
34. Clasen R, Schupp M, Foryst-Ludwig A, Sprang C, Clemenz M, Krikov M, Thöne-Reineke C, Unger T, Kintscher U. PPARg-activating angiotensin type-1 receptor blockers induce adiponectin. Hypertension 2005; 46: 137-143.
35. Benson SC, Pershadsingh HA, Ho CI, Chittiboyina A, Desai P, Pravenec M, Qi N, Wang J, Avery MA, Kurtz TW. Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARg-modulating activity. Hypertension 2004; 43: 993-1002.